Background. We hypothesized that poor control of Epstein-Barr virus (EBV) infection, leading
INTRODUCTION
Epstein-Barr virus (EBV) is a γ-herpesvirus that infects the great majority of adults worldwide, usually since childhood, resulting in life-long infection. Following primary infection, EBV typically enters a latent phase, in which EBV DNA persists as a closed circular nuclear genome (episome) in a subpopulation of resting memory B cells (1) . Regulation of the established EBV infection in a healthy host involves a cellular immune response featuring EBV-specific cytotoxic T-lymphocytes that keep the number of infected B cells in check (2) . Poorly-controlled EBV infection, such as that observed in clinical states of immune dysregulation, is characterized by B cell proliferation and lytic replication of the EBV genome (3) . Even in an immunocompetent host, spontaneous activation occurs in a small proportion of infected B cells (4) . EBV infection can also be transiently reactivated in response to physical or psychological stressors (5, 6) .
There is compelling evidence for an etiologic role of EBV in certain B-cell lymphoid diseases including endemic Burkitt lymphoma (4, 7) , aggressive lymphoproliferative disease seen in people who have severe immunodeficiencies (4, 7), HIV-related lymphomas (8) , and lymphomas in the elderly (9) . Many of the NHL tumor cells in these patients carry a monoclonal form of the EBV genome (i.e., are EBV-positive tumors), indicating that the tumor arose from a single infected cell and suggesting a direct effect of EBV on lymphomagenesis (3, 7) . EBV has also been postulated as a risk factor for NHL in the general (primarily immunocompetent) population (10) . EBV is not detected in the majority of these tumors (11) ; therefore, a direct role of EBV in an immortalizing transformation of lymphocytes is less likely in these cases.
However, alternative pathways have been hypothesized for a causal role of poorly-controlled EBV infection in NHL occurring in the general population, such as EBV-induced stimulation of B-cell proliferation (10) , which increases the pool of B cells in which transforming mutations can occur or can promote clonal expansion in already-transformed B cells. Another proposed alternative pathway is a "hit-and-run" mechanism in which EBV antigens or other infectioninduced molecules cause mutations that initiate or promote lymphomagenesis, followed by loss of EBV episomes from the clonal tumor cell line (1, 12, 13) .
The hypothesis that EBV may be associated with NHL in the general population has been investigated in several prospective cohort studies, in which antibodies to EBV antigens measured in prediagnostic serum samples were used to characterize control of established EBV infection (10, (14) (15) (16) (17) . Persons who have established infection with EBV typically have IgG antibodies specific to the viral capsid antigen (VCA) and nuclear antigen type 1 (EBNA1); therefore, most adults test seropositive for these antibodies. However, elevated titers of anti-VCA and anti-EBNA may imply poor of control of EBV-transformed cells (18, 19) . Antibodies to early antigen (EA) are seen less frequently and reflect viral replication (i.e., reactivation) (14, 20) . The previous epidemiologic studies provide some evidence of an abnormal pattern of EBV serology preceding NHL diagnosis, including several studies finding an association with elevated anti-EA titers (10, 14, 15) . However, inconsistencies in the methods and results of the previous studies leave the role of EBV in NHL open to interpretation.
We investigated the association between EBV and risk of NHL in a case-control study nested within the Women's Health Initiative Observational Study (WHI OS) prospective cohort.
Our hypothesis was that poor control of established EBV infection, as reflected by relatively high levels of antibodies to EBV antigens (IgG to VCA, EBNA1, and EA-D), is a causal factor for NHL in the general population of primarily immunocompetent persons. We limited our study to B-cell NHL based on a hypothesized mechanism of EBV-induced B-cell proliferation leading to increased rates of critical mutations. Our study is the largest to date on this topic, allowing well-powered estimation of EBV-related risks by major NHL subtypes -an important contribution given that the one previous study to examine subtypes found differences in risk (16) . In addition to serology, we evaluated risk of NHL according to EBV DNA load, a measure used frequently in patient groups (EBV DNA load is a strong predictor for the development of lymphoproliferative disorders among transplant patients (21-23)), but not yet examined as a quantitative risk factor in general population studies of NHL.
MATERIALS AND METHODS
The study was designed as a nested case-control study in the WHI OS. All study activities were approved by Human Subjects review by the FHCRC IRB (IR #6897).
Study Population
The design of the WHI OS and clinical trials has been published previously (24) . The OS includes 93,676 community-dwelling, postmenopausal women enrolled between 1994 and 1998 at 40 clinical centers distributed widely throughout the US, including targeted enrollment of minority women.
We included 491 B-cell NHL cases diagnosed before April 2009. Women were mailed questionnaires annually to report a wide variety of outcomes including cancers of any type.
Patient charts were reviewed by coders trained in Surveillance, Epidemiology, and End-Results (SEER) program guidelines to classify the case morphology according to the ICD-O-3 coding (25) . Excluded were women with cancer history (except non-melanoma skin cancer) at enrollment (n=88) or incident cancer during follow-up but before the NHL diagnosis (n=34), and cases without a control match (n=2; see below). B-cell NHL cases were further grouped based on the World Health Organization and the International Lymphoma Epidemiology Consortium We selected one control for each of the cases from WHI OS participants who had never been diagnosed with cancer (except non-melanoma skin cancer) at the time of case diagnosis.
Each control was selected from the pool of eligible non-cases living at the time of a case diagnosis, and was individually matched to the corresponding case by age (±1 year), US region (Northeast, South, Midwest, West), and date of enrollment blood draw (±3 months).
EBV Biomarker Measurement
We conducted multiplexed assays for the determination of antibodies to EBV in serum samples from the WHI study baseline, collected an average of 6 years before NHL diagnosis (or control reference date). IgG antibodies to several EBV-encoded antigens, including VCA, EBV DNA load was measured at the University of Washington Diagnostic Molecular Virology Laboratory. The DNA samples were from the WHI baseline or later follow-up visits (i.e., the DNA samples were not necessarily from the same blood draw as the serum samples from the study baseline used for antibody measurements), but for all subjects, were collected before the case diagnosis date (or control reference date). 464 cases and 469 controls had available 1-μg DNA samples with appropriate collection timing. The final selected samples were collected, on average, 3.9 years before diagnosis. A detailed description of the methods for EBV DNA load determination is presented as an Appendix. In brief, the EBV PCR assay used primers specifically designed for this study, which amplified a repetitive area in the IR-1 
Statistical Analysis
All analyses were performed using the SAS system, version 9.2 (SAS Institute, Cary, NC). We generated odds ratios (ORs) and 95% confidence intervals (CIs) as estimates of relative risks of the association between B-cell NHL and each EBV measure, using conditional logistic regression (29) . In addition to adjustment for the study matching factors, we evaluated a set of potential confounders selected a priori, including race/ethnicity (coded as 'Black or African American', 'White, not Hispanic', and 'Other'), education (grouped into 7 categories and evaluated as a continuous variable), body mass index (BMI, continuous), and smoking status (coded as 'Former', 'Current', and 'Never'). Potential confounding was evaluated by the change in the effect estimate for a specific EBV measure when including the covariate in the model compared to the model without the covariate.
All of the EBV measures were analyzed first as dichotomous variables, estimating risks for positive versus negative in order to determine risk associated with mere presence of the marker. We limited all analyses of EBNA1, EA-D, and EBV DNA to participants who were seropositive for VCA, indicating an established EBV infection. We also evaluated the EBV measures as categorical variables (with cutpoints defined according to the distribution of each measure among control subjects) in order to evaluate whether NHL risk differed by quantified value of the EBV measure, without any a priori assumption about the fit of the relationship. We evaluated etiologic heterogeneity by fitting unconditional polytomous logistic regression models for major subtypes of B-cell NHL (including CLL/SLL/PLL, DLBCL, and FL) and testing for homogeneity of risk estimates among the subtypes. If the p-value in the test for homogeneity among subtypes was <0.05, we then conducted pairwise comparisons to test for heterogeneity in the magnitude of risk estimates between specific subtypes. To describe the patterns of association between EBV measures and NHL according to the number of years between blood sample collection and NHL diagnosis ('prediagnostic interval'), we conducted polytomous logistic regression analyses with NHL cases classified according to time intervals of <4, 4-7, ≥8 years.
We performed several subanalyses to evaluate consistency of our findings. We estimated risks separately by ages <65 and ≥65, and tested for interaction by age group on the multiplicative scale. To further evaluate the magnitude of the main associations of interest among otherwise apparently immunocompetent subjects, we conducted subanalyses in which we excluded subjects who reported at baseline that they had ever been diagnosed with certain conditions or taken medications known to be characterized by/cause altered immune status.
Specifically, exclusions were based on a list of conditions queried in a baseline medical history questionnaire, which included physician diagnoses of systemic lupus erythematosus, rheumatoid arthritis, colitis, diverticulitis, pancreatitis, kidney stones, gallbladder disease, stomach ulcer, 
goiter, and asthma (but did not include other conditions of interest such as allergy). In addition, we excluded women who reported having taken glucocorticosteroid medications or diseasemodifying antirheumatic drugs. Analyses with these exclusions included 346 cases and 349 controls.
RESULTS
Our study population of postmenopausal women (Table 1 ) was mostly 60 years and older at the study baseline (>80% of controls), of white, not Hispanic race/ethnicity (85%), and educated beyond high school (>80%). Approximately half of the women never smoked, and more than half were classified as overweight or obese (BMI ≥25; >60%). The EBV measure values did not differ significantly by the matching factors: age, US region, or blood draw date (not shown).
Associations between the EBV measures and B-cell NHL are shown in Table 2 . There was no evidence of confounding by the covariates selected a priori (race/ethnicity, education, smoking, BMI); therefore, we present risk estimates adjusted for the matching factors only.
There was no apparent association between seropositivity for the VCA antigen 
reporting immune-related medical conditions or medications (not shown). There was no association between the level of antibody to EBNA1 antigen and risk of NHL.
There was a weak suggestion of increased B-cell NHL risk associated with seropositivity for the EBV EA-D antigen (Table 2) 
DISCUSSION
We hypothesized that poorly-controlled EBV infection, leading to reactivation, increases the risk of B-cell NHL in the general population. The prospective design of the WHI OS and the banked samples offered a valuable resource to measure EBV markers in prediagnostic samples in a sizable study of postmenopausal women. We found that seropositivity to EBNA1 was associated with decreased risk of B-cell NHL, overall and for each of the histologic subtypes examined.
However, we found no association between the levels of antibody to EBNA1 or VCA and NHL undiagnosed NHL caused EBV reactivation rather than EBV reactivation playing a causal role in lymphomagenesis; this scenario is supported by our finding that the associations with CLL/SLL/PLL were strongest for cases with the shortest time interval between blood draw and diagnosis. Although none of these scenarios can be proven from the data at hand, we provide further interpretation, below.
We found that women who were seropositive for IgG to EBNA1 (93.4% of control women with evidence of established EBV infection) were at decreased risk of developing B-cell NHL or, conversely, seronegativity to EBNA1 was associated with increased risk. Two previous cohort studies found non-significant reduced risks associated with EBNA seropositivity (10, 14) .
EBNA1 is expressed in all latently infected cells and is required for maintenance of EBV genome in the B cell as a circular DNA episome (4). Although anti-EBNA1 levels have been shown to be elevated in chronic EBV reactivation and in certain types of cancer (19) , there is also evidence that EBNA1 expression may be lost when a lytic (replicative) cycle ensues. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. (22) . Therefore, it is possible that the increased risk of NHL associated with EBNA1 seronegative status relates to a shift to EBV activation. Alternatively, it is possible that the presence of antibody to EBNA1 may simply reflect a more robust immune system, resulting in more efficient regulation of EBV infection and also improved means to prevent lymphomagenesis (whether caused by EBV or other factors). This alternative explanation is aligned with our results for the FL subtype, for which we observed a strongly reduced risk associated with EBNA1 seropositivity, but no association with any of the other measures of active EBV infection.
Similar to other studies on this topic conducted in general population samples, we found the most consistent EBV-NHL associations for the CLL/SLL/PLL subtype. A large study nested in the Physicians' and Nurses' Health Study cohorts (N=340 cases) found no evidence that antibodies to EBV antigens were associated with NHL overall, although there were some risk increases observed for CLL/SLL in relation to elevated anti-EBNA2 titer (typically seen in persistently active EBV infection) and lower EBNA1/EBNA2 ratio (16) . A history of infectious mononucleosis (caused by delayed primary EBV infection) was associated with increased risk of NHL in an analysis of InterLymph consortium studies, and the strongest association was observed for the CLL/SLL/PLL/MCL subtype (30) . In a study that used immunoblot analysis to characterize antibody diversity patterns, an abnormal EBV serologic pattern was found among CLL/SLL cases (40% of cases vs. 18% of controls), but not in other NHL subtypes (31) 
CLL/SLL/PLL are EBV-negative neoplasms, a causal mechanism for EBV is hypothesized to involve stimulation of B-cell proliferation and/or induced expression of molecules with known potential for causing oncogenic mutations (i.e., a 'hit-and-run' mechanism), such as AID and pol-η (33-35) . In our study, associations of CLL/SLL/PLL with anti-EA-D and EBV DNA were stronger for cases with a shorter time interval between blood draw and diagnosis, suggesting either that EBV acts as a late stage carcinogen for CLL/SLL/PLL or that the association may be due to reverse causastion, from EBV reactivation in response to underlying immune dysregulation that typically precedes CLL/SLL diagnosis. Features of immune dysregulation in CLL patients include decreased immunoglobulin production and antibody response, cytokine production abnormalities, abnormal immunoregulatory T-cell function, and diminished natural killer cell function (36) ; however, the length of time that such immune impairment precedes diagnosis is not well described. CLL/SLL is preceded in virtually all instances by small, preclinical clonal lymphocyte expansions termed "monoclonal B-cell lymphocytosis" (MBL) (37, 38) , indicating an early pathogenic process, and use of such a biomarker to exclude persons with early signs of disease may be useful in future studies to help tease out a causal role of EBV. 
